Last October, Sanofi stunned the healthcare industry by firing CEO Chris Viehbacher, who was best-known for spearheading the French pharma giant’s $20 billion acquisition of Genzyme three years earlier. Now Viehbacher has reemerged as managing partner of Gurnet Point Capital, a new $2 billion healthcare venture capital and private equity fund bankrolled by the Bertarelli family (founders of Serono, which was sold to Merck KGaA for $13.3 billion in 2007).
Cambridge, Mass.-based GPC has actually been around for more than a year, but to date has disclosed only one investment.
Fortune spent some time on the phone with Viehbacher, to better understand his plans. What follows is an edited transcript of our conversation:
FORTUNE: Why join an investment firm, rather than seek out another operating role?
Viehbacher: Because I spent pretty much the last 30 years in the operating space and, when I left Sanofi, I thought a lot…
View original post 697 more words